231.38
-11.38
(-4.69%)
Jun 19 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 231.29 - 244.70 |
| 52 week | 107.31 - 283.99 |
| Open | 243.38 |
| Vol / Avg. | 0.00/794,372.00 |
| Mkt cap | 22.67B |
| P/E | 31.28 |
| Div/yield | - |
| EPS | 7.40 |
| Shares | 97.97M |
| Beta | 1.01 |
| Inst. own | 76% |
Events
Jul 22, 2013
Q2 2013 Regeneron Pharmaceuticals Earnings Release
Jun 14, 2013
Regeneron Pharmaceuticals Annual Shareholder Meeting
Jun 11, 2013
Regeneron Pharmaceuticals at Goldman Sachs Healthcare Conference
Jun 3, 2013
Regeneron Pharmaceuticals at Jefferies Global Healthcare Conference
May 29, 2013
Regeneron Pharmaceuticals at Deutsche Bank dbAccess Health Care Conference
May 20, 2013
Regeneron Pharmaceuticals at UBS Global Healthcare Conference
May 14, 2013
Regeneron Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 10, 2013
Regeneron Pharmaceuticals at Credit Suisse Antibody Day
May 8, 2013
Regeneron Pharmaceuticals at Robert W Baird and Co Growth Stock Conference
May 3, 2013
Q1 2013 Regeneron Pharmaceuticals Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 22.49% | 54.43% |
| Operating margin | 34.81% | 33.20% |
| EBITD margin | - | 35.88% |
| Return on average assets | 18.21% | 44.08% |
| Return on average equity | 29.91% | 86.68% |
| Employees | 1,950 | - |
| Carbon Disclosure Rating | - | - |
Address
STE 10, 777 Old Saw Mill River Road
TARRYTOWN, NY 10591-6707
United States - Map
+1-914-8477000 (Phone)
+1-914-3472113 (Fax)
TARRYTOWN, NY 10591-6707
United States - Map
+1-914-8477000 (Phone)
+1-914-3472113 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.
Officers and directors
| P. Roy Vagelos M.D. | Chairman of the Board | |
| Leonard S. Schleifer M.D., Ph.D. | President, Chief Executive Officer, Director | |
| Murray A. Goldberg | Chief Financial Officer, Senior Vice President - Finance and Administration, Assistant Secretary | |
| Joseph J. LaRosa | Senior Vice President, General Counsel, Secretary | |
| Daniel P. Van Plew | Senior Vice President, General Manager - Industrial Operations and Product Supply | |
| Peter Powchik M.D. | Senior Vice President - Clinical Development | |
| Neil Stahl Ph.D. | Senior Vice President - Research and Development Sciences | |
| Robert J. Terifay | Senior Vice President - Commercial | |
| George D. Yancopoulos M.D., Ph.D. | Chief Scientific Officer and President - Regeneron Laboratories, Director | |
| Douglas S. McCorkle | Vice President, Controller, Assistant Treasurer |